Exploring environmental modifiers of LRRK2-associated Parkinson's disease penetrance: An exposomics and metagenomics pilot study on household dust

被引:0
|
作者
Andujar, Begona Talavera [1 ]
Pereira, Sandro L. [1 ]
Busi, Susheel Bhanu [1 ,2 ]
Usnich, Tatiana [3 ]
Borsche, Max [3 ,4 ]
Ertan, Sibel [5 ]
Bauer, Peter [6 ]
Rolfs, Arndt [6 ]
Hezzaz, Soraya [1 ]
Ghelfi, Jenny [1 ]
Brueggemann, Norbert [3 ,4 ]
Antony, Paul [1 ]
Wilmes, Paul [1 ,7 ]
Klein, Christine [3 ]
Gruenewald, Anne [1 ]
Schymanski, Emma L. [1 ]
机构
[1] Univ Luxembourg, Luxembourg Ctr Syst Biomed LCSB, L-4367 Belvaux, Luxembourg
[2] UK Ctr Ecol & Hydrol, Wallingford, Oxon, England
[3] Univ Lubeck, Inst Neurogenet, Lubeck, Germany
[4] Univ Lubeck, Dept Neurol, Lubeck, Germany
[5] Koc Univ, Sch Med, Dept Neurol, Istanbul, Turkiye
[6] CENTOGENE GmbH, Rostock, Germany
[7] Univ Luxembourg, Fac Sci Technol & Med, Dept Life Sci & Med, L-4362 Esch Sur Alzette, Luxembourg
关键词
Indoor environment; Exposomics; Metagenomics; Parkinson's disease; Leucine-rich repeat kinase 2 (LRRK2); Bisphenol S; MASS-SPECTROMETRY; MITOCHONDRIAL DYSFUNCTION; OXIDATIVE STRESS; PIPECOLIC ACID; IN-VITRO; MANAGEMENT; RELEVANCE; FIPRONIL; BACTERIA;
D O I
10.1016/j.envint.2024.109151
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Pathogenic variants in the Leucine-rich repeat kinase 2 (LRRK2) gene are a primary monogenic cause of Parkinson's disease (PD). However, the likelihood of developing PD with inherited LRRK2 pathogenic variants differs (a phenomenon known as "reduced penetrance"), with factors including age and geographic region, highlighting a potential role for lifestyle and environmental factors in disease onset. To investigate this, household dust samples from four different groups of individuals were analyzed using metabolomics/exposomics and metagenomics approaches: PD+/LRRK2+ (PD patients with pathogenic LRRK2 variants; n = 11), PD-/LRRK2+ (individuals with pathogenic LRRK2 variants but without PD diagnosis; n = 8), iPD (PD of unknown cause; n = 11), and a matched, healthy control group (n = 11). The dust was complemented with metabolomics and lipidomics of matched serum samples, where available. A total of 1,003 chemicals and 163 metagenomic operational taxonomic units (mOTUs) were identified in the dust samples, of which ninety chemicals and ten mOTUs were statistically significant (ANOVA p-value < 0.05). Reduced levels of 2-benzothiazolesulfonic acid (BThSO3) were found in the PD-/LRRK2+ group compared to the PD+/LRRK2+ . Among the significant chemicals tentatively identified in dust, two are hazardous chemical replacements: Bisphenol S (BPS), and perfluorobutane sulfonic acid (PFBuS). Furthermore, various lipids were found altered in serum including different lysophosphatidylethanolamines (LPEs), and lysophosphatidylcholines (LPCs), some with higher levels in the PD+/LRRK2+ group compared to the control group. A cellular study on isogenic neurons generated from a PD+/LRRK2+ patient demonstrated that BPS negatively impacts mitochondrial function, which is implicated in PD pathogenesis. This pilot study demonstrates how non-target metabolomics/exposomics analysis of indoor dust samples complemented with metagenomics can prioritize relevant chemicals that may be potential modifiers of LRRK2 penetrance.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] A study of LRRK2 mutations and Parkinson's disease in Brazil
    Goncalves Pimentel, Marcia Mattos
    Vasconcelos Moura, Karla Cristina
    Abdalla, Claudia Bueno
    Pereira, Joao Santos
    Zuma de Rosso, Ana Lucia
    Nicaretta, Denise Hack
    Campos Junior, Mario
    de Almeida, Richard Morais
    dos Santos, Jussara Mendonca
    Constantino Bastos, Izabel Cristina
    Xavier Mendes, Maria Filomena
    Maultasch, Henryk
    de Rezende Costa, Flavio Henrique
    dos Santos Werneck, Antonio Luiz
    Santos-Reboucas, Cintia Barros
    NEUROSCIENCE LETTERS, 2008, 433 (01) : 17 - 21
  • [22] Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease
    Ben Sassi, Samia
    Nabli, Fatma
    Hentati, Emna
    Nahdi, Houda
    Trabelsi, Meriam
    Ben Ayed, Hela
    Amouri, Rim
    Duda, John Eric
    Farrer, Matthew John
    Hentati, Faycal
    PARKINSONISM & RELATED DISORDERS, 2012, 18 (03) : 243 - 246
  • [23] Molecular biology changes associated with LRRK2 mutations in Parkinson's disease
    Lu, Yi Wei
    Tan, Eng-King
    JOURNAL OF NEUROSCIENCE RESEARCH, 2008, 86 (09) : 1895 - 1901
  • [24] Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score
    Iwaki, Hirotaka
    Blauwendraat, Cornelis
    Makarious, Mary B.
    Bandres-Ciga, Sara
    Leonard, Hampton L.
    Gibbs, J. Raphael
    Hernandez, Dena G.
    Scholz, Sonia W.
    Faghri, Faraz
    Nalls, Mike A.
    Singleton, Andrew B.
    MOVEMENT DISORDERS, 2020, 35 (05) : 774 - 780
  • [25] Penetrance in Parkinson's Disease Related to the LRRK2 R1441G Mutation in the Basque Country (Spain)
    Ruiz-Martinez, Javier
    Gorostidi, Ana
    Ibanez, Berta
    Alzualde, Ainhoa
    Otaegui, David
    Moreno, Fermin
    Lopez de Munain, Adolfo
    Bergareche, Alberto
    Carlos Gomez-Esteban, Juan
    Marti Masso, Jose F.
    MOVEMENT DISORDERS, 2010, 25 (14) : 2340 - 2345
  • [26] Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease
    Brown, Emmeline E.
    Blauwendraat, Cornelis
    Trinh, Joanne
    Rizig, Mie
    Nalls, Mike A.
    Leveille, Etienne
    Ruskey, Jennifer A.
    Jonvik, Hallgeir
    Tan, Manuela M. X.
    Bandres-Ciga, Sara
    Hassin-Baer, Sharon
    Brockmann, Kathrin
    Infante, Jon
    Tolosa, Eduardo
    Ezquerra, Mario
    Ben Romdhan, Sawssan
    Benmahdjoub, Mustapha
    Arezki, Mohamed
    Mhiri, Chokri
    Hardy, John
    Singleton, Andrew B.
    Alcalay, Roy N.
    Gasser, Thomas
    Grosset, Donald G.
    Williams, Nigel M.
    Pittman, Alan
    Gan-Or, Ziv
    Fernandez-Santiago, Ruben
    Brice, Alexis
    Lesage, Suzanne
    Farrer, Matthew
    Wood, Nicholas
    Morris, Huw R.
    NEUROBIOLOGY OF AGING, 2021, 97 : 148.e17 - 148.e24
  • [27] Low Levels of LRRK2 Gene Expression are Associated with LRRK2 SNPs and Contribute to Parkinson’s Disease Progression
    Selma Yılmazer
    Esin Candaş
    Gençer Genç
    Merve Alaylıoğlu
    Büşra Şengül
    Ayşegül Gündüz
    Hülya Apaydın
    Güneş Kızıltan
    Sibel Ertan
    Erdinç Dursun
    Duygu Gezen-Ak
    NeuroMolecular Medicine, 2021, 23 : 292 - 304
  • [28] Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease
    da Silva, Camilla P.
    Abreu, Gabriella de M.
    Cabello Acero, Pedro H.
    Campos Junior, Mario
    Pereira, Joao S.
    Ramos, Sarah R. de A.
    Nascimento, Caroline M.
    Voigt, Danielle D.
    Rosco, Ana Lucia
    Araujo Leite, Marco A.
    Vasconcellos, Luiz Felipe R.
    Nicaretta, Denise H.
    Della Coletta, Marcus V.
    da Silva, Delson Jose
    Goncalves, Andressa P.
    dos Santos, Jussara M.
    Calassara, Veluma
    Valenca, Debora Cristina T.
    Martins, Cyro J. de M.
    Santos-Reboucas, Cintia B.
    Pimentel, Marcia M. G.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 160 - 164
  • [29] Lrrk2 mutations in south america: a study of Chilean Parkinson's disease
    Perez-Pastene, Carolina
    Cobb, Stephanie A.
    Diaz-Grez, Fernando
    Hulihan, Mary A.
    Miranda, Marcelo
    Venegas, Pablo
    Godoy, Osvaldo Trujillo
    Kachergus, Jennifer M.
    Ross, Owen A.
    Layson, Luis
    Farrer, Matthew J.
    Segura-Aguilar, Juan
    NEUROSCIENCE LETTERS, 2007, 422 (03) : 193 - 197
  • [30] High frequency and reduced penetrance of lRRK2 g2019S mutation among Parkinson's disease patients in Cantabria (Spain)
    Sierra, Maria
    Gonzalez-Aramburu, Isabel
    Sanchez-Juan, Pascual
    Sanchez-Quintana, Coro
    Miguel Polo, Jose
    Berciano, Jose
    Combarros, Onofre
    Infante, Jon
    MOVEMENT DISORDERS, 2011, 26 (13) : 2343 - 2346